Loading provider…
Loading provider…
Gastroenterology Physician in Chicago, IL
NPI: 1366756140Primary Practice Location
RUSH UNIVERSITY MEDICAL CENTER
1620 W Harrison St, Chicago, IL
Primary Employer
Rush University Internists
rush.edu
HQ Phone
Get MD Atsushi's Phone Numberphone_androidMobile
Get MD Atsushi's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
IL State Medical License
2012 - 2026
IN State Medical License
2023 - 2025
TX State Medical License
2023 - 2025

American Board of Internal Medicine
Internal Medicine
Keio Gujuku University School of Medicine
Medical School
Until 1997
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 45380Biopsy of the large bowel using an endoscope (colonoscopy) | 59 | 59 |
| 2 | G0500Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 47 | 47 |
| 3 | 45385Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 38 | 38 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 22 | 23 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 13 | 14 |
Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis.
Authors: Austin Kaboff, John Lim, Anas Almoghrabi, John Kwon
Publication Date: 2015-09-16
Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease.
Authors: Parita Patel
Publication Date: 2019-12-11
Lead Sponsor: Takeda
Collaborators: Takeda Development Center Americas, Inc.
Intervention / Treatment: DRUG: TAK-018, DRUG: TAK-018 Placebo